Multiple sclerosis mortality in New Zealand: a nationwide prospective study.

Ruth LeadbetterMichael MacAskillDaniell J MyallBruce V TaylorPurwa Joshinull nullDeborah F Mason

Published in: Journal of neurology, neurosurgery, and psychiatry (2023)

New Zealanders with MS have a median survival age 7.2 years lower than the general population and twice the mortality risk. The survival gap was greater for progressive-onset disease and for those with an early age of onset.

Keyphrases

multiple sclerosis
white matter
free survival
mass spectrometry
cardiovascular events
ms ms
cross sectional
risk factors
coronary artery disease